Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Cellular Biomedicine Group
company
About
CBMG is a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancers and stem cell therapies.
- 101 - 250
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $120M
- Industries
- Biotechnology,Medical Device,Therapeutics
- Founded date
- Jan 1, 2009
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Cellular Biomedicine Group is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. It is the result of the acquisition, transfer, commercialization, and advancement of thirty years of research and human treatment experience in cellular medicine. Its cellular research and development is the result of collaboration among scientists and doctors from the US, England, and China.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$120M
Cellular Biomedicine Group has raised a total of
$120M
in funding over 2 rounds. Their latest funding was raised on
Sep 28, 2021 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 28, 2021 | Series A | $120M | 1 |
AstraZeneca
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Cellular Biomedicine Group is funded by 1 investors.
AstraZeneca
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
AstraZeneca
|
Yes | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
